Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Juni 2021 02:00 ET | Quelle: ORPHAZYME A/S

Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research

Orphazyme A/SCompany announcement No. 21/2021Company Registration No. 32266355 Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today...
28. Juni 2021 00:00 ET | Quelle: ORPHAZYME A/S

Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC

Orphazyme A/SCompany announcement No. 20/2021Inside informationCompany Registration No. 32266355 -Significant headcount reduction of global workforce to free resources- -Changes to the...
24. Juni 2021 07:31 ET | Quelle: ORPHAZYME A/S

Major shareholder announcement

Orphazyme A/SCompany announcement No. 19/2021Company Registration No. 32266355 Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
23. Juni 2021 05:43 ET | Quelle: ORPHAZYME A/S

Major shareholder announcement

Orphazyme A/SCompany announcement No. 18/2021Company Registration No. 32266355 Copenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
18. Juni 2021 01:00 ET | Quelle: ORPHAZYME A/S

Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C

Orphazyme A/SCompany announcement No. 16/2021Inside informationCompany Registration No. 32266355 Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage...
15. Juni 2021 11:05 ET | Quelle: ORPHAZYME A/S

Major shareholder announcement

Orphazyme A/SCompany announcement No. 16/2021Company Registration No. 32266355 Copenhagen, Denmark, June 15, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
11. Juni 2021 03:42 ET | Quelle: ORPHAZYME A/S

Orphazyme addresses recent trading activity

Orphazyme A/SCompany announcement No. 15/2021Company Registration No. 32266355 Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering...
07. Mai 2021 01:00 ET | Quelle: ORPHAZYME A/S

Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

Orphazyme A/SCompany announcementNo. 14/2021Inside informationCompany Registration No. 32266355 Pivotal trial did not meet primary and secondary endpoints evaluating impact on function and...
27. April 2021 16:05 ET | Quelle: ORPHAZYME A/S

Orphazyme to present at upcoming investor conferences

Orphazyme A/SInvestor news No. 05/2021Company Registration No. 32266355 Copenhagen, Denmark and Chicago, IL, USA, April 27, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage...
22. April 2021 00:34 ET | Quelle: ORPHAZYME A/S

New long-term share-based incentive program

Orphazyme A/SCompany announcement No. 13/2021Company Registration No. 32266355 Copenhagen, Denmark, April 22, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical...

Vorherige Seite

Nächste Seite